Spineology launched OptiMesh HA Nano, a combination of the company’s proprietary OptiMesh expandable interbody implant platform with Promimic’s HA Nano Surface technology.
OptiMesh HA Nano technology integrates a nano-thin hydroxyapatite surface treatment designed to create an ultra-hydrophilic absorption environment that supports cellular interaction at the bone/implant interface. The HA Nano surface is intended to promote rapid cellular response and establish a three-dimensional bioactive surface area, with the goal of accelerating osseointegration and reducing the potential risk of infection. This patented surface technology has been shown to enhance biological performance by encouraging stronger and faster bonding between bone and implant.
“This addition of the HA Nano technology to the OptiMesh portfolio underscores our continued commitment to innovation and patient-specific care,” said Brian Snider, Chief Executive Officer of Spineology. “The OptiMesh platform is uniquely built on our conform and expand implant technology that adapts to individual patient anatomy. Now, Spineology delivers a first-of-its-kind solution that integrates a well-studied surface treatment, optimized to support spinal fusion goals, and promote osseointegration.”
Spineology launched OptiMesh HA Nano, a combination of the company's proprietary OptiMesh expandable interbody implant platform with Promimic's HA Nano Surface technology.
OptiMesh HA Nano technology integrates a nano-thin hydroxyapatite surface treatment designed to create an ultra-hydrophilic absorption environment that supports cellular...
Spineology launched OptiMesh HA Nano, a combination of the company’s proprietary OptiMesh expandable interbody implant platform with Promimic’s HA Nano Surface technology.
OptiMesh HA Nano technology integrates a nano-thin hydroxyapatite surface treatment designed to create an ultra-hydrophilic absorption environment that supports cellular interaction at the bone/implant interface. The HA Nano surface is intended to promote rapid cellular response and establish a three-dimensional bioactive surface area, with the goal of accelerating osseointegration and reducing the potential risk of infection. This patented surface technology has been shown to enhance biological performance by encouraging stronger and faster bonding between bone and implant.
“This addition of the HA Nano technology to the OptiMesh portfolio underscores our continued commitment to innovation and patient-specific care,” said Brian Snider, Chief Executive Officer of Spineology. “The OptiMesh platform is uniquely built on our conform and expand implant technology that adapts to individual patient anatomy. Now, Spineology delivers a first-of-its-kind solution that integrates a well-studied surface treatment, optimized to support spinal fusion goals, and promote osseointegration.”
Copy to clipboard 
